-
264%
OncQuer(TM) JMML panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerOncQuer(TM) JMML panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer -
264%
OncQuer(TM) MDS Panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerOncQuer(TM) MDS Panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer -
264%
OncQuer(TM) MPN Panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerOncQuer(TM) MPN Panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer -
265%
ONCQUER(TM) MRD PANEL
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerONCQUER(TM) MRD PANEL
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer -
265%
OncQuer(TM) MYD88 Mutation Tes ...
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerOncQuer(TM) MYD88 Mutation Tes ...
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer -
265%
OncQuer(TM) Myeloid Panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerOncQuer(TM) Myeloid Panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer -
272%
OncQuerTM Canassist Test
Identification of therapeutically relevant gene mutations for Cancer -
265%
OncQuerTM Focus Panel
Identification of therapeutically relevant gene mutations for Cancer -
272%
ONCQUERTM SARCOMA PANEL
Identification of therapeutically relevant gene mutations for Cancer
